Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH)

Purpose: Several risk stratification tools may be used to estimate the risk of adverse outcomes, monitor disease progression, and inform treatment decision-making in PAH. In TORREY, a randomized placebo-controlled phase 2 study, the tyrosine kinase inhibitor seralutinib met its primary endpoint of reduction in pulmonary vascular resistance (PVR) at 24 weeks (NCT04456998). A post-hoc exploratory analysis evaluated changes in REVEAL 2.0, REVEAL Lite 2, COMPERA 2.0 and Non-Invasive French risk tools with treatment.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , R. Osterhout, S. Hoffman, R.T. Zamanian, A.R. Hemnes, R.N. Channick, K.M. Chin, R.P. Frantz, A. Ghofrani, L.S. Howard, V.V. McLaughlin, J. Vachiery, L.S. Zisman, M. Cravets, J. Bruey, R.F. Roscigno, D. Mottola, R. Aranda, O. Sitbon Source Type: research